ArticleCells2019
The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation.
Article in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Clinical Impact of Eltrombopag-Associated Iron Chelation in Adults with Immune Thrombocytopenia: A Multicenter Real-World Study.Mediterranean journal of hematology and infectious diseases · 2026Article
- Cx43 mediates cross-talk of tumor cells and macrophage via cGAS-STING signaling.Medical oncology (Northwood, London, England) · 2025Article
- Isolation methods, proliferation, and adipogenic differentiation of adipose-derived stem cells from different fat depots in bovines.Molecular and cellular biochemistry · 2024Article
- Long term use of eltrombopag in children with chronic immune thrombocytopenia: extended real life retrospective multicenter experience of the Italian Association of Pediatric Hematology and Oncology.Frontiers in medicine · 2023Article
- The Immune-Specific E3 Ubiquitin Ligase MARCH1 Is Upregulated during Human Cytomegalovirus Infection to Regulate Iron Levels.Journal of virology · 2022Article
- Iron status influences the response of cord blood megakaryocyte progenitors to eltrombopag in vitro.Blood advances · 2022Article
- Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (MFrontiers in molecular biosciences · 2022Article
- Exploring the Potential of Eltrombopag: Room for More?Frontiers in pharmacology · 2022Article
- Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Article
- Identification of Eltrombopag as a Repurposing Drug Against Staphylococcus epidermidis and its Biofilms.Current microbiology · 2021Article
- Repurposing Eltrombopag as an Antimicrobial Agent Against Methicillin-ResistantFrontiers in microbiology · 2021Article
- Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2.Journal of microbiology and biotechnology · 2020Article
- Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in TurkeyTurkish journal of haematology : official journal of Turkish Society of Haematology · 2020Article
- The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?Pharmacological research · 2020Review
- Promoting platelets is a therapeutic option to combat severe viral infection of the lung.Blood advances · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
The thrombopoietin receptor agonist eltrombopag was successfully used against human cytomegalovirus (HCMV)-associated thrombocytopenia refractory to immunomodulatory and antiviral drugs. These effects were ascribed to the effects of eltrombopag on megakaryocytes. Here, we tested whether eltrombopag may also exert direct antiviral effects. Therapeutic eltrombopag concentrations inhibited HCMV replication in human fibroblasts and adult mesenchymal stem cells infected with six different virus strains and drug-resistant clinical isolates. Eltrombopag also synergistically increased the anti-HCMV activity of the mainstay drug ganciclovir. Time-of-addition experiments suggested that eltrombopag interfered with HCMV replication after virus entry. Eltrombopag was effective in thrombopoietin receptor-negative cells, and the addition of Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.